Topical absorbable hemostats market seen reaching $3.03B by 2030

The topical absorbable hemostats market is projected to rise from $2.17 billion in 2025 to $3.03 billion by 2030, driven by more surgeries, better hospital infrastructure and demand for faster recovery. North America led in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Topical absorbable hemostats help control bleeding during surgery and trauma care without needing to be removed after use. - The market’s growth tracks with higher procedure volumes, especially in orthopedic and cardiothoracic surgery, and with broader pressure to reduce blood loss and improve patient safety. - Rising demand matters for hospitals, ambulatory surgical centers and device makers as systems look for faster procedures and shorter stays.

What happened: - The Business Research Company projects the topical absorbable hemostats market will grow from $2.17 billion in 2025 to $2.32 billion in 2026. - The market is forecast to reach $3.03 billion by 2030, at a 6.9% compound annual growth rate. - The report identifies North America as the largest regional market in 2025. - The Asia-Pacific region is expected to post the fastest growth during the forecast period. - The company also published a free sample report and the full market report.

The details: - The report ties growth to more orthopedic and cardiothoracic surgeries, broader use of traditional hemostats, better hospital infrastructure in developed countries, a high incidence of trauma and bleeding disorders, and stronger focus on surgical safety. - The forecast period also reflects innovation in absorbable hemostatic materials and wider use of minimally invasive surgery. - Expansion of ambulatory surgical centers, an aging global population, and demand for quicker recovery times and shorter hospital stays are also supporting the market. - Key trends include more minimally invasive procedures, a surge in surgical volumes, greater emphasis on minimizing blood loss, growth in outpatient surgical facilities, and development of biocompatible, fast-absorbing hemostats. - Topical absorbable hemostats are applied directly to a bleeding site and are absorbed by the body over time, which removes the need for surgical removal. - The report says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast implies demand is being shaped less by a single procedure type and more by a broad shift toward higher-volume, lower-recovery surgical care. - Faster growth in Asia-Pacific suggests the strongest upside may come from expanding access to surgery and improving clinical infrastructure, not just from mature markets. - The emphasis on biocompatible and fast-absorbing products points to competition around performance, convenience and operating-room efficiency. - An aesthetic surgery benchmark cited in the report showed nearly 35 million procedures in 2023, up 3.4% to 34.9 million total surgical and non-surgical procedures, underscoring how procedure growth can lift demand for bleeding-control products.

What's next: - Market expansion will likely continue as more procedures shift to outpatient settings and minimally invasive techniques. - Hospitals and surgical centers are expected to keep prioritizing products that reduce bleeding, support safety and speed recovery. - The report’s regional split suggests North America will remain a major revenue base while Asia-Pacific becomes the main growth engine.

The bottom line: - Topical absorbable hemostats are moving from a niche surgical tool to a faster-growing category tied to global procedure growth and healthcare efficiency.